Seeking Alpha

Citi negative on Sarepta, Ariad for 2014, shares slide

  • Shares of Sarepta Therapeutics (SRPT) are off 5.7% premarket.
  • Likely behind the move is Citi, where SRPT is a top sell idea for 2014, along with Ariad Pharmaceuticals (ARIA).
  • On SRPT, Citi doesn't "anticipate that [the] FDA will reverse its view that eteplirsen's Phase 2 data is not sufficient to file [making] the path ahead ... risky, lengthy, and expensive."
  • On ARIA: "We expect the [Iclusig] re-launch to be challenging with a tightly restricted label and headwinds."
  • ARIA -6.5% premarket
Comments (13)
  • Flog
    , contributor
    Comments (203) | Send Message
     
    And People are listening to CITI, a corrupt bank? Citi has their own problems and should take care of their own business!
    ARIA is a LIFE drug! Long ARIA!!!!
    6 Jan, 09:33 AM Reply Like
  • mehedi
    , contributor
    Comments (15) | Send Message
     
    Always does this when they want to buy something. CITI is doing politics. I'm sure Iclusing is life saving drug in a big demand. Many Intellectual head of Aria is not caring about that. They are about to find many new drug for cancer patient and so on. This company is returning on their previous high $ 20 this year. Strong buy.....
    6 Jan, 12:15 PM Reply Like
  • toosmarttofail
    , contributor
    Comments (585) | Send Message
     
    ARIA is a "whammy" stock that likes to screw over investors.

     

    The drugs have problems: deadly side effects, and stemcells will make them obsolete within five years. I wouldn't touch this company. Try ACTC or other stem cell companies like PSTI or ATHX.
    6 Jan, 12:44 PM Reply Like
  • NSmytheson
    , contributor
    Comments (84) | Send Message
     
    Seriously? ACTC is an OTC company that has done nothing BUT screw over investors. It's been sitting at seven cents forever, with a gazillion shares outstanding. I'd rather gamble with Ariad, thanks.
    8 Jan, 10:45 AM Reply Like
  • Flog
    , contributor
    Comments (203) | Send Message
     
    Take you ACTC stock at less than .06 a share and sell 100 shares of them and you can have enough money for a beer. Sell quickly before you can not even get a beer!
    Sticking to ARIA!
    6 Jan, 01:53 PM Reply Like
  • toosmarttofail
    , contributor
    Comments (585) | Send Message
     
    Might as well buy REGN at $280-300 or GOOG at $1,1100+ if you think share price means everything.
    7 Jan, 03:11 PM Reply Like
  • Flog
    , contributor
    Comments (203) | Send Message
     
    Well there are 2 great stocks you mention!
    Anyone who tells investors that a stock at .06 is great, has no investment knowledge, just a wild gambler! ARIA will be over $10 very soon.
    7 Jan, 08:32 PM Reply Like
  • mehedi
    , contributor
    Comments (15) | Send Message
     
    Cancer patients are always with deadly disease with mantally and physically. No matter what...it will happen with Iclusing ....no risk no gain and rest will b gifted by God.... So Iclusing would b in demand and improve day by day by the Head of intellectual people in Aria. Watch the 14 Jan conference you will get what it is going be...... Long Aria.
    6 Jan, 03:50 PM Reply Like
  • loganj2
    , contributor
    Comments (48) | Send Message
     
    As usual, "toosmarttofail" adds his two, or should I say, six cents. It would be interesting to hear what the scientific basis is for his comments and if he has a group of advisors who truly understand the drug and the company. I do, and I am long on Aria because the drugs the company has developed have very good market potential. This is beside the personal interest I have in the success of Iclusig that I have previously mentioned in this forum. If he lost money on Aria he is not alone, I, along with many others did too. The flip side is that I have managed my risk and recouped. The company still has a bright outlook and can reward prudent investors. Perhaps he overextended himself and needs a forum to vent? Vent away - it is good humor to read. There are a few thousand of us who have "bet our lives" on this company and we are the real risk takers and the real winners.
    6 Jan, 05:34 PM Reply Like
  • toosmarttofail
    , contributor
    Comments (585) | Send Message
     
    This stock's chart speaks for itself.

     

    Wait until the lawsuits hit. The drug has serious side effects, and will give way to stemcell companies who will probably CURE whatever this drug treats. All of medicine is about to change.

     

    I worked for a top research medical center in 1993, at the center of the Genome project, when gene therapy was in its embryonic stages. The doctors for and with whom I worked took for granted that "dinosaur" drugs would one day give way to stem treatments.

     

    Beware of anyone who makes personal attacks against those who dissent, while trying to convince you to part with your money. That's always bad news.

     

    This stock has plenty of downside potential, and I've been saying this since it was punshing $8, sa well as when it hit $5.50. It's up off the $5.50, but only after hitting $4.17 first. No matter what it does, it has too much "surprise" potnetial for my taste. I'll stick with ACTC, PSTIw, and NWBOw as my best recommendations. Also starting to like OSIR a lot since it hasn't done much recently.
    7 Jan, 03:15 PM Reply Like
  • 901Wizard
    , contributor
    Comments (32) | Send Message
     
    BS. Long ARIA. Not selling under $20.
    6 Jan, 06:01 PM Reply Like
  • FatCat22
    , contributor
    Comments (10) | Send Message
     
    ARIA is a long shot. More reason to go down then up, lawsuits will be next along with a need to raise money. Way to risky of a way to lose your money. One thing you will never see is $20 again. People that think it's going back to it's previous prices don't know anything about this stock or what happens after it drops like this.
    7 Jan, 04:30 AM Reply Like
  • loganj2
    , contributor
    Comments (48) | Send Message
     
    Toosmarttofail - You do realize that Iclusig is a genetically targeted drug and that the Genome project has substantially contributed to the development of all tyrosine kinase inhibitors? Stem cel therapy may very we'll be the future but it is a long way off. I hold my position that there is a future for Iclusig and Ariad. 20 would be over blown but low to mid teens is realistic. It will probably peak there and start to taper off unless the second drug in their pipeline meets with success.
    8 Jan, 01:06 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector